3-Pivalyloxy-4-pivalyloxymethoxybenzaldehyde | 81377-77-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 3-Pivalyloxy-4-pivalyloxymethoxybenzaldehyde
• 英文别名: [2-(2,2-dimethylpropanoyloxy)-4-formylphenoxy]methyl 2,2-dimethylpropanoate
• CAS: 81377-77-7
• 化学式: C₁₈H₂₄O₆
• 分子量: 336.385
• InChiKey: LZZJGHFRHHDQPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  特戊酸氯甲酯 、 3,4-二羟基苯甲醛 在 三乙胺 作用下， 以 水 、 N,N-二甲基甲酰胺 、 Petroleum ether 为溶剂， 生成 3-Pivalyloxy-4-pivalyloxymethoxybenzaldehyde
  参考文献：
  名称：

  Novel sypathomimetic amine prodrugs

  摘要：

  新颖、短暂的前药形式的酚类二羟基交感胺具有以下结构式(I)：##STR1## 其中X为O、S或NR.sup.5；n为1或2；当n为1时，R.sup.1为酚类、核二羟基天然交感胺的单去氢基残基，当n为2时，R.sup.1为酚类、核二羟基天然交感胺的双去氢基残基；R.sup.2选自以下组成：直链或支链烷基，碳原子数为1至20；芳基，碳原子数为6至10；环烷基，碳原子数为3至8；烯基，碳原子数为2至20；环烯基，碳原子数为4至8；炔基，碳原子数为2至20；芳基烷基，烷基芳基，芳基烯基，芳基炔基，烯基芳基，炔基芳基，低酰氧烷基和羧基烷基，其中烷基、芳基、烯基和炔基的定义如上所述；饱和或不饱和的单杂环或多杂环，或融合的杂环，其中每个杂环中含有1至3个N、S或O的杂原子，并且每个这样的环从3到8环；上述的单取代或多取代衍生物，每个取代基选自以下组成：低烷基、低烷氧基、低酰基、低酰氧基、卤素、卤代低烷基、氰基、羰乙氧基、低烷硫基、氨基、硝基、低烷基氨基、二低烷基氨基、羧基、氨基甲酰基、低烷基氨基甲酰基和##STR2## 其中R.sup.4为氢或碳原子数为1至10的烷基；R.sup.3为氢、R.sup.2、低酰基、氰基、卤代低烷基、氨基甲酰基、低烷氨基甲酰基、二低烷基氨基甲酰基、--CH.sub.2 ONO.sub.2和--CH.sub.2 OCOR.sup.2；R.sup.5为氢或低烷基；(ii)结构式(II)：##STR3## 其中X、R.sup.2和R.sup.3如上定义，R.sup.1为酚类、核二羟基天然交感胺的双去氢基残基；(iii)结构式(I)或(II)中的任一种，其中##STR4## 为任何天然存在的蛋白氨基酸的残基，任何N-取代的天然氨基酸的残基，该N-取代基是低烷基或可通过氢解或水解裂解的氨基酸保护基，或N、N-低二烷基或C.sub.4 -C.sub.7环烷氨基酸的残基；(iv)其无毒、药用可接受的盐。

  公开号：

  US04313956A1

文献信息

• Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0046270A1

  公开（公告）日：1982-02-24

  Novel transient prodrug forms of bio-affecting phenolic compounds are selected from the group consisting of those having the structural formula (I): wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl; R1 is the mono- or polydehydroxylated residue of a non-steroidal bio-affecting phenol, with the proviso that R' is other than a monohydroxylated or didehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine; R2 is selected from the group consisting of straight or branched chain alkyl, aryl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, alkynylaryl, (lower acyloxy)alkyl, and carboxyalkyl; 3- to 8-membered, saturated or unsaturated mono-heterocyclic or polyheterocyclic containing from 1 to 3 of any one or more of the heteroatoms N, S or O; and mono- or polysubstituted derivatives of the above; R3 is hydrogen, lower acyl, cyano, halo(lower alkyl), carbamyl, lower alkylcarbamyl, di(lower alkyl)carbamyl, CH2ONO2, -CH2OCOR2 or any non-heterocyclic member of the group defined by R2 above; and n is at least one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): wherein X, R', R2 and R3 are as defined above, and n and m are each at least one and the sum of n+m equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol either etherified via a R2COXCH(R3)0-moiety or esterified via a R2COO-moiety; and the pharmaceutically acceptable acid addition salts, quaternary ammonium salts and N-oxides thereof.

  生物效应酚类化合物的新型瞬效原药形式选自具有结构式(I)的化合物组成的组： 其中 X 是 O、S 或 NR5，其中 R5 是氢或低级烷基；R1 是非类固醇生物效应酚的单羟基或多羟基残基，但 R' 不是酚、核二羟基天然交感胺或拟交感胺的单羟基或双羟基残基；R2 选自直链或支链烷基、芳基、环烷基、烯基、环烯基、炔基、芳烷基、烷芳基、芳烯基、芳炔基、烯芳基、炔芳基、（低级酰氧基）烷基和羧基烷基组成的组；R3 是氢、低级酰基、氰基、卤代（低级烷基）、氨甲酰基、低级烷基氨甲酰 基、二（低级烷基）氨甲酰基、CH2ONO2、-CH2OCOR2 或上述 R2 定义的基团中的任何非杂环成员；且 n 至少为 1，等于通过 R2COXCH(R3)0 子代醚化的非甾体生物作用酚所包含的酚羟基官能团的总数；具有结构式（II）的酚羟基官能团： 其中 X、R'、R2 和 R3 如上文所定义，n 和 m 至少各为 1，且 n+m 之和等于非甾体类生物效应酚通过 R2COXCH(R3)0 子键醚化或通过 R2COO 子键酯化的酚羟基官能团的总数；及其药学上可接受的酸加成盐、季铵盐和 N-氧化物。
• US4313956A
  申请人：——

  公开号：US4313956A

  公开（公告）日：1982-02-02
• Novel sypathomimetic amine prodrugs
  申请人：INTERx Research Corp.

  公开号：US04313956A1

  公开（公告）日：1982-02-02

  Novel, transient prodrug forms of the phenolic dihydroxy sympathomimetic amines have (i) the structural formula (I): ##STR1## wherein X is O, S or NR.sup.5 ; n is 1 or 2; R.sup.1 is the monodehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine when n is 1, and the didehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine when n is 2; R.sup.2 is selected from the group consisting of straight or branched chain alkyl having from 1 to 20 carbon atoms; aryl having from 6 to 10 carbon atoms; cycloalkyl having from 3 to 8 carbon atoms; alkenyl having from 2 to 20 carbon atoms; cycloalkenyl having from 4 to 8 carbon atoms; alkynyl having from 2 to 20 carbon atoms; aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, alkynylaryl, loweracyloxyalkyl, and carboxyalkyl, wherein alkyl, aryl, alkenyl and alkynyl are as defined above; saturated or unsaturated monoheterocyclic or polyheterocyclic, or fused heterocyclic, containing from 1 to 3 of any one or more of the hetero atoms N, S or O in each heterocyclic ring thereof and each such ring being from 3- to 8-membered; and mono-or poly-substituted derivatives of the above, each of said substituents being selected from the group consisting of lower alkyl, lower alkoxy, lower acyl, lower acyloxy, halo, haloloweralkyl, cyano, carbethoxy, loweralkylthio, amino, nitro, loweralkylamino, diloweralkylamino, carboxyl, carbamyl, loweralkylcarbamyl, diloweralkylcarbamyl and ##STR2## wherein R.sup.4 is hydrogen or alkyl having from 1 to 10 carbons; R.sup.3 is hydrogen, R.sup.2, lower acyl, cyano, haloloweralkyl, carbamyl, loweralkylcarbamyl, diloweralkylcarbamyl, --CH.sub.2 ONO.sub.2 and --CH.sub.2 OCOR.sup.2 ; R.sup.5 is hydrogen or lower alkyl; (ii) the structural formula (II): ##STR3## wherein X, R.sup.2 and R.sup.3 are as defined above and R.sup.1 is the didehydroxylated residue of a phenolic, nuclear dihydroxy natural sympathetic or sympathomimetic amine; (iii) either of the structural formulae (I) or (II) wherein ##STR4## is the residue of any naturally occurring protein amino acid, the residue of any N-substituted naturally occurring amino acid, which N-substituent is lower alkyl or any amino acid protective group cleavable via hydrogenolysis or hydrolysis, or the residue of an N, N-lower dialkyl or C.sub.4 -C.sub.7 cycloalkylamino acid; and (iv) the non-toxic, pharmaceutically acceptable salts thereof.

  新颖、短暂的前药形式的酚类二羟基交感胺具有以下结构式(I)：##STR1## 其中X为O、S或NR.sup.5；n为1或2；当n为1时，R.sup.1为酚类、核二羟基天然交感胺的单去氢基残基，当n为2时，R.sup.1为酚类、核二羟基天然交感胺的双去氢基残基；R.sup.2选自以下组成：直链或支链烷基，碳原子数为1至20；芳基，碳原子数为6至10；环烷基，碳原子数为3至8；烯基，碳原子数为2至20；环烯基，碳原子数为4至8；炔基，碳原子数为2至20；芳基烷基，烷基芳基，芳基烯基，芳基炔基，烯基芳基，炔基芳基，低酰氧烷基和羧基烷基，其中烷基、芳基、烯基和炔基的定义如上所述；饱和或不饱和的单杂环或多杂环，或融合的杂环，其中每个杂环中含有1至3个N、S或O的杂原子，并且每个这样的环从3到8环；上述的单取代或多取代衍生物，每个取代基选自以下组成：低烷基、低烷氧基、低酰基、低酰氧基、卤素、卤代低烷基、氰基、羰乙氧基、低烷硫基、氨基、硝基、低烷基氨基、二低烷基氨基、羧基、氨基甲酰基、低烷基氨基甲酰基和##STR2## 其中R.sup.4为氢或碳原子数为1至10的烷基；R.sup.3为氢、R.sup.2、低酰基、氰基、卤代低烷基、氨基甲酰基、低烷氨基甲酰基、二低烷基氨基甲酰基、--CH.sub.2 ONO.sub.2和--CH.sub.2 OCOR.sup.2；R.sup.5为氢或低烷基；(ii)结构式(II)：##STR3## 其中X、R.sup.2和R.sup.3如上定义，R.sup.1为酚类、核二羟基天然交感胺的双去氢基残基；(iii)结构式(I)或(II)中的任一种，其中##STR4## 为任何天然存在的蛋白氨基酸的残基，任何N-取代的天然氨基酸的残基，该N-取代基是低烷基或可通过氢解或水解裂解的氨基酸保护基，或N、N-低二烷基或C.sub.4 -C.sub.7环烷氨基酸的残基；(iv)其无毒、药用可接受的盐。